ClinicalTrials.gg

Program

Carboplatin

Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.

Furthest: phase 4, since Nov 24, 200989 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly300 open or runningphase 4since Nov 24, 2009Apr 30, 2002none ahead
Bristol-Myers Squibb140 open or runningphase 4since May 28, 2014Sep 13, 2001none ahead
Sanofi70 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Institute31 open or runningphase 2since Nov 2, 2005Nov 2, 2005none ahead
Swedish Orphan Biovitrum30 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
ago-research-gmbh20 open or runningphase 3since Apr 16, 2013Apr 16, 2013none ahead
carthera21 open or runningphase 3since Jun 5, 2023Nov 13, 2018Jan 28, 2028phase 3 · NCT05902169
Eisai20 open or runningphase 3since Dec 31, 2002Dec 31, 2002none ahead
InSightec20 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Ionis Pharmaceuticals20 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead
Johnson & Johnson21 open or runningphase 3since Aug 31, 2020Jun 12, 2008none ahead
bebetter-med-inc10 open or runningphase 2since Nov 11, 2024Nov 11, 2024none ahead
Biocad10 open or runningphase 3since Dec 27, 2012Dec 27, 2012none ahead
CASI Pharmaceuticals10 open or runningphase 2since Nov 13, 2002Nov 13, 2002none ahead
cytran10 open or runningphase 2since Jun 6, 2001Jun 6, 2001none ahead
galvanize-therapeutics-inc10 open or runningphase 4since Oct 13, 2022Oct 13, 2022none ahead
gradalis-inc10 open or runningphase 2since May 29, 2013May 29, 2013none ahead
hope-cancer-institute-inc10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead
Innovent Biologics10 open or runningphase 3since Oct 23, 2016Oct 23, 2016none ahead
mabscale-llc11 open or runningphase 3since Dec 8, 2022Dec 8, 2022Dec 2026phase 3 · NCT05654454
matrix-pharmaceutical10 open or runningphase 2since Aug 10, 2001Aug 10, 2001none ahead
NovoCure10 open or runningphase 2since Mar 19, 2015Mar 19, 2015none ahead
optimum-therapeutics-llc10 open or runningphase 2since Dec 22, 2009Dec 22, 2009none ahead
Pharmacosmos10 open or runningphase 2since Nov 18, 2016Nov 18, 2016none ahead
shanghai-huaota-biopharmaceutical-co-ltd11 open or runningphase 3since Jan 13, 2026Jan 13, 2026Apr 10, 2028phase 3 · NCT07360132
sotio-a-s10 open or runningphase 2since Apr 4, 2014Apr 4, 2014none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Mar 15, 2012Mar 15, 2012none ahead
theradex10 open or runningphase 3since Oct 11, 2001Oct 11, 2001none ahead
UCB10 open or runningphase 2since Sep 6, 2005Sep 6, 2005none ahead
windy-hill-medical-inc10 open or runningphase 2since Apr 28, 2008Apr 28, 2008none ahead
Zydus Lifesciences10 open or runningphase 2since Jan 21, 2000Jan 21, 2000none ahead

Also a collaborator on its studies: Daiichi Sankyo, AstraZeneca, Merck, jazz-pharmaceuticals-ireland-limited, parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, novotech-australia-pty-limited, wuxi-cds-clinical-research-shanghai-co-ltd, Valerio Therapeutics, ortho-biotech-inc, tibotec-pharmaceutical-limited and medarex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Sep 12, 2005.

  1. Oct 23, 2016Innovent Biologics's first study: phase 3 study in NSCLCNew to Innovent BiologicsInnovent Biologics · NCT02954172 · 450 enrolled · China
  2. Nov 18, 2016Pharmacosmos's first study: phase 2 study in Triple Negative Breast NeoplasmsNew to PharmacosmosPharmacosmos · NCT02978716 · 102 enrolled · United States, Belgium, Bulgaria and more
  3. Dec 16, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT02998528 · 505 enrolled · United States, Argentina, Brazil and more
  4. Sep 26, 2018Phase 3 study in Ovarian Neoplasmsago-research-gmbh · NCT03690739 · 9 enrolled · Germany
  5. Nov 13, 2018carthera's first study: phase 2 study in GlioblastomaNew to cartheracarthera · NCT03744026 · 38 enrolled · United States, France
  6. Jun 1, 2020InSightec's first studies: 2 phase 2 studies in GlioblastomaNew to InSightecInSightec · NCT04417088, NCT04440358
  7. Aug 31, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04538664 · 308 enrolled · United States, Australia, Belgium and more
  8. Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT04702880 · 135 enrolled · United States, Australia, Belgium and more
  9. Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
  10. Oct 13, 2022galvanize-therapeutics-inc's first study: phase 4 study in Lung NeoplasmsNew to galvanize-therapeutics-incgalvanize-therapeutics-inc · NCT05583188 · 5 enrolled · United States
  11. Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
  12. Jun 5, 2023Phase 3 study in Glioblastomacarthera · NCT05902169 · 560 enrolled · United States, Austria, Belgium and more
  13. Nov 11, 2024bebetter-med-inc's first study: phase 2 study in Advanced Triple-Negative Breast CancerNew to bebetter-med-incbebetter-med-inc · NCT06685796 · 65 enrolled · China
  14. Jan 13, 2026shanghai-huaota-biopharmaceutical-co-ltd's first study: phase 3 study in Squamous Non-small Cell Lung CancerNew to shanghai-huaota-biopharmaceutical-co-ltdshanghai-huaota-biopharmaceutical-co-ltd · NCT07360132 · 480 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
  2. Jan 28, 2028Primary completion: phase 3 study in Glioblastomacarthera · NCT05902169
  3. Apr 10, 2028Primary completion: phase 3 study in Squamous Non-small Cell Lung Cancershanghai-huaota-biopharmaceutical-co-ltd · NCT07360132

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 89 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07360132Squamous Non-small Cell Lung Cancer · China3Not yet recruitingshanghai-huaota-biopharmaceutical-co-ltdApr 10, 2028480
NCT06685796Advanced Triple-Negative Breast Cancer · China2Completedbebetter-med-incApr 20, 202665
NCT05902169Glioblastoma · United States, Austria, Belgium and more3Active, not recruitingcartheraJan 28, 2028560
NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation3Recruitingmabscale-llcDec 2026620
NCT05583188Lung Neoplasms · United States4Terminatedgalvanize-therapeutics-incFeb 8, 20245
NCT05136677Mesothelioma, Malignant · China2CompletedBristol-Myers SquibbNov 12, 2025102
NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbMay 22, 2025135
NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonMay 3, 2023308
NCT04440358Glioblastoma · Canada, Italy, South Korea2CompletedInSightecNov 30, 202313
NCT04417088Glioblastoma · United States2CompletedInSightecNov 30, 202328
NCT03744026Glioblastoma · United States, France2CompletedcartheraJun 23, 202138
NCT03690739Ovarian Neoplasms · Germany3Terminatedago-research-gmbhMar 3, 20219
NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3CompletedBristol-Myers SquibbSep 8, 2021505
NCT02978716Triple Negative Breast Neoplasms · United States, Belgium, Bulgaria and more2TerminatedPharmacosmosJun 28, 2019102
NCT02954172NSCLC · China3CompletedInnovent BiologicsOct 19, 2018450
NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more2WithdrawnEli LillyDec 20170
NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbOct 25, 20242,747
NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more2CompletedNovoCureApr 201882
NCT02392507Carcinoma · United States2CompletedEli LillyJan 29, 201854
NCT02289456Carcinoma, Non-Small-Cell Lung · United States2CompletedBristol-Myers SquibbFeb 22, 201740
NCT02151149Carcinoma, Non-Small-Cell Lung · United States4CompletedBristol-Myers SquibbJul 14, 2017143
NCT02107937Ovarian Neoplasms · Czechia, Poland2Completedsotio-a-sNov 2020136
NCT01881230Breast Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbOct 28, 2016191
NCT01867086Ovarian Neoplasms · United States2Completedgradalis-incApr 20161
NCT01837251Ovarian Neoplasms · Australia, Austria, Belgium and more3Completedago-research-gmbhJan 2021682
NCT01763645Carcinoma, Non-Small-Cell Lung · Belarus, India, Russian Federation and more3CompletedBiocadNov 2014353
NCT01563601Small Cell Lung Carcinoma3WithdrawnTeva Pharmaceutical IndustriesMay 20160
NCT01445119Glioma · United States1CompletedEli LillyJul 201358
NCT01234038Carcinoma, Non-Small-Cell Lung · United States, Hungary, Poland and more2CompletedIonis PharmaceuticalsOct 2012116
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedEli LillyJan 2014280
NCT01087970Head and Neck Neoplasms · United States2CompletedEli LillyAug 201369
NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico2CompletedEli LillyAug 2013187
NCT01063075Head and Neck Neoplasms · United States, Canada2CompletedEli LillyMay 201534
NCT01075100Breast Neoplasms · United States2CompletedSarah Cannon Research InstituteJun 2013103
NCT01038752Carcinoma, Non-Small-Cell Lung · United States2Terminatedoptimum-therapeutics-llcNov 201214
NCT01020786Carcinoma, Non-Small-Cell Lung · Japan4CompletedEli LillyMar 2011109
NCT01004380Carcinoma, Ovarian Epithelial · United States1CompletedEisaiAug 201215
NCT00990912Pediatric Solid Tumors2CompletedBristol-Myers SquibbNov 200520
NCT00796991Advanced Melanoma · United States1CompletedBristol-Myers SquibbNov 200972
NCT00826852Lung Neoplasms · Turkey2CompletedSanofiJul 200949
NCT00756847Neoplasms · United States1CompletedSanofiMay 201252
NCT00698451Ovarian Neoplasms · United States2CompletedJohnson & JohnsonOct 201054
NCT00669747Carcinoma, Intraductal, Noninfiltrating · United States2UNKNOWNwindy-hill-medical-incSep 200945
NCT00576225NSCLC · United States3WithdrawnSwedish Orphan BiovitrumApr 5, 20100
NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more2TerminatedEli LillyOct 20084
NCT00490711Carcinoma, Ovarian Epithelial · Slovakia2CompletedEli Lilly7
NCT00482014Carcinoma, Non-Small-Cell Lung · United States, India2CompletedEli LillyOct 2011120
NCT00407407Fallopian Tube Neoplasms · United States1TerminatedBristol-Myers SquibbFeb 1, 20086
NCT00402051Carcinoma, Non-Small-Cell Lung · Germany2CompletedEli LillyDec 2008133
NCT00365365Breast Neoplasms · United States2CompletedSanofiOct 2011214
NCT00356525Lung Neoplasms · United States, Brazil, India2TerminatedEli LillyJun 200841
NCT00350792Carcinoma, Non-Small-Cell Lung · France2CompletedEli LillyNov 200862
NCT00343291Carcinoma, Non-Small-Cell Lung · United States2CompletedEli LillyMay 2010121
NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more2CompletedEli LillyApr 2010135
NCT00303108Breast Neoplasms · United States2CompletedSarah Cannon Research InstituteMar 2010136
NCT00269152Carcinoma, Non-Small-Cell Lung · France, Germany, Spain2CompletedEli LillyNov 2007122
NCT00258739Lung Neoplasms · Spain2CompletedSanofiSep 2007140
NCT00248287Breast Neoplasms · United States2Active, not recruitingSarah Cannon Research InstituteDec 2025154
NCT00191854Breast Neoplasms · Brazil, China, India and more2CompletedEli LillyAug 2008147
NCT00191451Breast Neoplasms · United States2CompletedEli LillyOct 2008150

How it is read

Names in the registry

  • “Carboplatin”, 110 entries
  • “carboplatin”, 38 entries
  • “Pemetrexed/Carboplatin”, 2 entries
  • “CARBOPLATIN”, 2 entries
  • “Carboplatin/Paclitaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Carboplatin (Eli Lilly): development program | ClinicalTrials.gg